Current Partnerships

ViroPharma understands the value of leveraging strategic relationships with companies whose strengths are additive our own. As such, we have established alliances with other pharmaceutical and biotechnology companies. (NOTE: This is not a complete list, and full detail is not provided for the companies listed below. For full detail and a complete list, please see ViroPharma's most recent annual report on form10K)

Last Modified: November 2009
Information contained in this section is only current as of the above date. Although we make a good faith effort to update the content of our web site periodically, we do not have a duty to update information contained in our web site, and we will not be liable for any failure to update such information.

Cinryze

Through our acquisition of Lev Pharmaceuticals in 2008, we are a party to a Distribution and Manufacturing Services Agreement with Sanquin as of January 16, 2004. Under this agreement, Sanquin has granted us (i) the exclusive right to distribute, market, offer for sale, sell, import and promote C1-INH derived from human plasma manufactured by Sanquin for the treatment of HAE in Israel and in all countries in North America and South America (other than certain Dutch territories, Argentina and Brazil), and (ii) a right of first refusal to distribute, market, offer for sale, sell, import and promote C1-INH derived from human plasma manufactured by Sanquin for the treatment of HAE in certain other geographic regions and under certain conditions.

Vancocin Capsules and Lilly

In November 2004, we acquired all rights in the U.S. and its territories to manufacture, market and sell Vancocin, the oral capsule formulation of vancomycin hydrochloride, as well as rights to certain related vancomycin products, from Lilly. Vancocin is a potent antibiotic approved by the FDA to treat antibiotic-associated pseudomembranous colitis caused by  C. difficile  and enterocolitis caused by  S. aureus , including methicillin-resistant strains. Lilly retained its rights to vancomycin outside of the U.S. and its territories.

Cytomegalovirus and GlaxoSmithKline

In August 2003, we entered into a license agreement with GlaxoSmithKline (GSK) under which we acquired worldwide rights (excluding Japan) to an antiviral compound, maribavir, for the treatment of CMV disease. Maribavir is a benzimidazole compound that was in development by GSK for the treatment of CMV retinitis in HIV positive patients.   Under the terms of the agreement, we have exclusive worldwide rights (excluding Japan) to develop and commercialize maribavir for the prevention and treatment of cytomegalovirus infections related to transplant (including solid organ and hematopoietic stem cell / bone marrow transplantation), congenital transmission, and in patients with HIV infection. The patents covering maribavir expire in 2015.